Nektar Therapeutics (NASDAQ:NKTR) CEO Howard W. Robin sold 33,333 shares of the stock in a transaction on Tuesday, May 21st. The shares were sold at an average price of $32.93, for a total value of $1,097,655.69. Following the completion of the transaction, the chief executive officer now owns 328,659 shares of the company’s stock, valued at $10,822,740.87. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.
NASDAQ:NKTR traded up $0.99 during trading hours on Friday, hitting $34.06. 60,192 shares of the company were exchanged, compared to its average volume of 1,734,829. Nektar Therapeutics has a one year low of $29.22 and a one year high of $92.17. The company has a quick ratio of 14.83, a current ratio of 14.94 and a debt-to-equity ratio of 0.21. The firm has a market cap of $5.83 billion, a P/E ratio of 9.01 and a beta of 2.96.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.71) by $0.03. Nektar Therapeutics had a return on equity of 37.63% and a net margin of 55.65%. The firm had revenue of $28.22 million during the quarter, compared to analyst estimates of $25.45 million. During the same period last year, the company posted ($0.60) EPS. As a group, equities research analysts expect that Nektar Therapeutics will post -3.14 EPS for the current year.
Hedge funds have recently bought and sold shares of the company. Meeder Asset Management Inc. raised its position in shares of Nektar Therapeutics by 150.2% in the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 479 shares in the last quarter. Quantamental Technologies LLC bought a new position in shares of Nektar Therapeutics in the 1st quarter worth about $27,000. CSat Investment Advisory L.P. raised its position in shares of Nektar Therapeutics by 279.2% in the 4th quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock worth $35,000 after acquiring an additional 790 shares in the last quarter. Laurel Wealth Advisors LLC bought a new position in shares of Nektar Therapeutics in the 4th quarter worth about $39,000. Finally, Sandy Spring Bank bought a new position in shares of Nektar Therapeutics in the 4th quarter worth about $59,000. 91.33% of the stock is owned by hedge funds and other institutional investors.
A number of research analysts have recently commented on NKTR shares. Mizuho reaffirmed a “buy” rating on shares of Nektar Therapeutics in a research report on Tuesday, February 19th. Piper Jaffray Companies set a $100.00 target price on Nektar Therapeutics and gave the stock a “buy” rating in a research report on Friday, March 1st. TheStreet raised Nektar Therapeutics from a “d+” rating to a “c” rating in a research report on Thursday, February 28th. HC Wainwright reaffirmed a “hold” rating and set a $47.00 target price on shares of Nektar Therapeutics in a research report on Tuesday, February 19th. Finally, ValuEngine raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, May 1st. One analyst has rated the stock with a sell rating, four have assigned a hold rating and nine have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $69.73.
Nektar Therapeutics Company Profile
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.
Featured Story: Treasury Bonds
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.